EN | TR
E-ISSN: 2651-2661 ISSN: 2651-2653
Golimumab using in ankylosing spondylitis patients: HUR-BIO/Spondyloarthritis real life experience
PDF
Cite
Share
Request
Clinical Research Article
VOLUME: 7 ISSUE: 1
P: 6-9
June 2015

Golimumab using in ankylosing spondylitis patients: HUR-BIO/Spondyloarthritis real life experience

J Turk Soc Rheumatol 2015;7(1):6-9
DOI: 10.2399/raed.15.02986
Abdulsamet Erden
Levent Kılıç
Ömer Karadağ
Ali Akdoğan
Şule Apraş Bilgen
Sedat Kiraz
İhsan Ertenli
Umut Kalyoncu
1. Hacettepe Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, Ankara
No information available.
No information available
Received Date: 12.12.2014
Accepted Date: 05.01.2015
PDF
Cite
Share
Request

ABSTRACT

Objective:

Anti-TNF therapies are known to be effective in Ankylosing spondylitis (AS) patients. Golimumab, an anti-TNF drug, have been available and get indication for AS patients in our country since January 2013. This study aimed to present the data on the efficacy of golimumab in patients with AS in a single center.

Methods:

Golimumab has been get indication in AS patients since January 2013 in our country. This study was conducted in May, 2014. In this study, 105 AS patients according to the New-York criteria and taking golimumab therapy were examined. Patients were divided into two groups such as; anti-TNF naive and before anti-TNF user. Demographic and clinical features of patients were recorded. DMARD usages before and after golimumab therapy were recorded. Before golimumab therapy; the acute phase responses were noted, BASDAI, BASFI, ASDAS-CRP, ASDAS-ESR scores were calculated. After golimumab therapy at month 3. BASDAI and 50% BASDAI response and at month 6. ASDAS-CRP response were recorded.

Results:

One hundred five AS patients were enrolled in this study. 60% of patients were male, mean age was 37.0 (8.8) years, mean duration of symptoms was 7.6 (6.3) years and mean duration of diagnosis was 5.5 (5.5) years. Of patients 55.5% (20/36) had HLA-B27 positivity, 6.5% had uveitis and 28.5% had positive family history. Before golimumab therapy 60% (63) of patients had been used DMARD and / or nonsteroidal anti-inflammatory drugs and 40% (42) of patients had been on anti-TNF drugs. In our patients with 6 months median follow-up period; at 3. month BASDAI 50% response in anti-TNF naive and before anti-TNF users were 48.5% and 35.0%, respectively. ASDAS-CRP clinically significany improvement rates at 6. month in anti-TNF naive and before anti-TNF users were 54.3% and 35.1%, respectively. After median follow-up 6 months; %80 of patients were continued golimumab therapy.

Conclusion:

In our study, golimumab was shown to be effective in about half of AS. Although golimumab is more effective in anti-TNF naive patients, but effectivity is obtained in before anti-TNF users also.